Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9841

Significant Association of Metabolic Indices, Lipid Profile, and Androgen Levels with Prostate Cancer  

Tewari, Reshu (Department of Pathology, King George's Medical University)
Chhabra, Mohini (Central Drug Research Institute (CSIRCDRI))
Natu, Shankar Madhavan (Department of Pathology, King George's Medical University)
Goel, Apul (Department of Urology, King George's Medical University)
Dalela, Divakar (Department of Urology, King George's Medical University)
Goel, Madhu Mati (Central Drug Research Institute (CSIRCDRI))
Rajender, Singh (Central Drug Research Institute (CSIRCDRI))
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9841-9846 More about this Journal
Abstract
Objectives: To compare the metabolic indices, lipid profile, androgens, and prostate specific antigen between prostate cancer and BPH and between grades of prostate cancer in a cross-sectional study. Materials and Methods: The study enrolled 95 cases of prostate cancer and 95 cases of benign prostatic hyperplasia (BPH). Prostate gland volume was measured using transrectal ultrasound. We compared insulin, testosterone, dihydrotestosterone, prostate specific antigen levels and lipid profile between prostate cancer of different grades and BPH. Further, prostate cancer patients were classified into low grade and high grade. Unpaired t-test for normally distributed variables and Man-Whitney U test for non-normal variables were used to assess differences. Results: We found that prostate cancer patients had significantly higher levels of insulin, testosterone, PSA, cholesterol, triglycerides, low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) in comparison to their BPH counterparts. Higher levels of these parameters also correlated with a higher grade of the disease. Conclusions: We conclude that higher levels of insulin, testosterone, PSA, and cholesterol correlate with a higher risk of prostate cancer, and also with a higher grade of the disease.
Keywords
Prostate cancer; BPH; lipid profile; testosterone; dihydrotestosterone; PSA;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Brawley OW (2003). Hormonal prevention of prostate cancer. Urol Oncol, 21, 2167-72.
2 Burke JP, Rhodes T, Jacobson DJ, et al (2006). Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol, 164, 41-6.   DOI   ScienceOn
3 Center MM, Jemal A, Lortet-Tieulent J, et al (2012). International variation in prostate cancer incidence and mortality rates. Eur Urol, 61, 1079-92.   DOI   ScienceOn
4 Clarke NW1, Hart CA, Brown MD (2009). Molecular mechanisms of metastasis in prostate cancer. Asian J Andro, 11, 57-67.   DOI
5 Clarke WN, Brown DM (2007). The Influence of Lipid Metabolism on Prostate Cancer Development and Progression: Is it Time for a Closer Look? Euro Urol, 52, 3-4.   DOI
6 Dandona P, Weinstock R, Thus k, et al (1998). Tumor necrosis factor -$\alpha$, in sera of obese patients fall with weight loss. J Clin Endocrinol Metab, 83, 2907-10.
7 Garfinkel L (1986). Overweight and mortality. Cancer, 58, 1826-29.   DOI
8 Gillitzer R, Pahernik S, Hampelc (2005). Relationship between prostate cancer and serum dyslipidemia. Urology, 66, 13-14.
9 Giovannucci E, Stampfer MJ, Krithivas K, et al (1997). The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A, 94, 3320-23.   DOI   ScienceOn
10 Girling JF, Whitaker HC, Mills IG (2007). Pathogenesis of prostate cancer and hormone refractory prostate cancer. Indian J Urol, 23, 35-42.   DOI
11 Gupta A, Gupta S, Pavuk M, Roehrborn CG (2006). Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology, 68, 1198-205.   DOI   ScienceOn
12 Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D (1998). Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 3, 157-62.
13 Hsing AW, Sakoda LC, Chua SC (2007). Obesity, metabolic syndrome, and prostate cancer. Amer J Clin Nutr, 86, 843-57.
14 Jaradeen, N (2010). Breast cancer risk-factors and breast self examination practice among Jordanian women. Bahrain Med Bulletin, 32, 1
15 Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C (2006). Serum lipid levels in benign prostatic hyperplasia. World J Urol, 24, 210-3.   DOI   ScienceOn
16 Long XJ, Lin S, Sun YN, Zheng ZF (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev, 13, 4097-100.   과학기술학회마을   DOI   ScienceOn
17 McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13.   과학기술학회마을   DOI   ScienceOn
18 Mitropoulos D, Ploumidou K, Voulgari K (2003) Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl, 63, 2-20.
19 Nandeesha H, Koner BC, Dorairajan LN, Sen SK (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta, 370, 89-93.   DOI
20 Nomura AM, Kolonel LN (1991). Prostate cancer: a current perspective. Epidemiol Rev, 13, 200-27.
21 Ozbek E, Otunctemur A, Dursun M, et al (2014). The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev, 15, 4029-32.   과학기술학회마을   DOI   ScienceOn
22 Pandeya DR, Mittal A, Sathian B, Bhatta B (2014). Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley. Asian Pac J Cancer Prev, 15, 1031-3.   과학기술학회마을   DOI   ScienceOn
23 Parsons JK, Bergstrom J, Barrett CE (2008). Lipids, Lipoproteins and Risk of benign prostatic hyperplasia in communitydwelling Men. BJU Int, 101, 313-8.   DOI   ScienceOn
24 Platz EA, Leitzmann MF, Visvanathan K, et al (2006). Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst, 98, 1819-25.   DOI   ScienceOn
25 Prabhat P, Tewari R, Natu SM, et al (2010). Is central obesity, hyperinsulinemia, and dyslipidemia associated with highgrade prostate cancer? A descriptive cross-sectional study. Ind J Uro, 26, 502-6.   DOI
26 Stephen JF, Brady JB (2005). Obesity and prostate cancer: a growing problem. Clin Cancer Res, 11, 6763-6.   DOI
27 Tewari R, Prabhat P, Natu SM, et al (2011). Association of benign prostatic hyperplasia (BPH) with metabolic syndrome (MS) and its components: A growing dilemma. J Men's Health, 8, 66-71.   DOI
28 Tewari R, Rajender S, Natu SM, et al (2012). Diet, obesity, and prostate health: are we missing the link? J Andro, 33, 763-76   DOI   ScienceOn
29 Wuermli L, Joerger M, Henz S, et al (2005). Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis, 8, 316-20.   DOI   ScienceOn
30 Tewari R, Rajender S, Natu SM, et al (2013). Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study. Cytokine, 10, 130-4.
31 Zeigler-Johnson CM, Walker AH, Mancke B et al (2002). Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered, 54, 13-21.   DOI
32 Zhang Q, Sun LJ, Qi J, Yang ZG, Huang T (2014). Influence of adipocytokines and periprostatic adiposity measurement parameters on prostate cancer aggressiveness. Asian Pac J Cancer Prev, 15, 1879-83.   과학기술학회마을   DOI
33 Zucchetto A, Tavani A, Dal ML, et al (2005). A history of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes, 29, 798-803.   DOI